antitumor agent 28

Antitumor agent-28 is a compound that specifically targets and inhibits the activity of the ataxia telangiectasia mutated (ATM) kinase. By doing so, it effectively impedes the progression of ATM-mediated diseases and demonstrates significant anti-cancer activity.

Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV, with EC50 values of 0.03 μM and 0.81 μM, respectively. It also demonstrates potential antitumor properties by inhibiting cancer cell lines HepG2, WI-38, Vero, and MCF-7, with IC50 values of 19.6, 39.3, 18.3, and 28 μM, respectively.

Antitumor agent-23 exhibits potent antitumoral activity, as demonstrated by its GI50 values of 38, 48, 5, 27, 80, and 28 nM against the lymphoma cell lines GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI respectively.

Antitumor agent-172 (Compound 28) acts as an inhibitor of the β-catenin BCL9 interaction, featuring an IC50 of 3.92 μM. This compound exhibits high affinity for β-catenin, with a Kd of 82 nM. Furthermore, Antitumor agent-172 activates T cells, enhances antigen presentation, and demonstrates antitumor activity along with favorable pharmacokinetic properties in murine models.